Projected effectiveness and added value of HIV vaccination campaigns in South Africa: A modeling study

Simon de Montigny, Blythe Adamson, Benoı̂t Mâsse, Louis P. Garrison, James G. Kublin, Peter B. Gilbert, Dobromir DimitrovScientific 2018 · DOI

Abstract

Promising multi-dose HIV vaccine regimens are currently under trial in South Africa. This study utilizes a dynamic economic mathematical model to estimate the potential epidemiological and economic impact of HIV vaccine campaigns compared to continuous vaccination. Assuming a partially effective vaccine (70% efficacy) with transient immune response, we found that biennial vaccination reaching 20% of the sexually active population could prevent between 480,000 and 650,000 HIV infections over a decade. At a launch price of $15 per dose, this strategy is cost-effective. Notably, mass vaccination campaigns were found to be consistently more effective and cost-efficient than continuous, clinic-based delivery.

Introduction: The Challenge of Imperfect Vaccines

Despite significant strides in antiretroviral therapy (ART) and pre-exposure prophylaxis (PrEP), HIV remains a critical public health priority in South Africa. While a vaccine is widely considered essential to ending the epidemic, current candidates—modeled after the RV144 Thai trial—often exhibit partial and transient efficacy. This study addresses a vital implementation question: how should an imperfect vaccine be deployed to maximize public health impact and economic value?

Methodology and Scenarios

The researchers employed a deterministic compartmental mathematical model to simulate HIV transmission among the 15–49-year-old population in South Africa. The model tracks individuals through infection stages, CD4 counts, and various treatment statuses.

A key feature of the model is its representation of "leaky" vaccine dynamics, where only a portion of recipients (72%) respond, and efficacy peaks shortly after the series before waning to zero over two years. To account for future uncertainties in ART scale-up, the study projected three baseline scenarios without vaccination: "Optimistic," "Main," and "Pessimistic."

Baseline projections for annual HIV incidence (A) and prevalence (B) in South Africa (2002–2027) under three scenarios without vaccination.

The economic analysis calculated the Incremental Cost-Effectiveness Ratio (ICER), representing the cost per Quality-Adjusted Life-Year (QALY) gained from a healthcare payer perspective.

Key Insights: Campaigns vs. Continuous Rollout

The Efficiency of Mass Campaigns

The study's most significant finding is that biennial mass vaccination campaigns "dominate" continuous, clinic-based vaccination. By vaccinating a large segment of the population simultaneously, the population-level "herd" benefit is realized more rapidly. This prevents more secondary transmissions than a slow, steady rollout reaching the same number of people over time.

The Coverage Paradox

While increasing coverage from 20% to 50% prevents a higher total number of infections, it decreases the marginal efficiency (infections prevented per 1,000 doses). Higher coverage levels eventually reach lower-risk individuals or those already indirectly protected by the existing vaccinated population, leading to diminishing returns on investment.

Price and Context Sensitivity

The cost-effectiveness of the program is highly sensitive to the vaccine's price. For the strategy to remain "good value" (below a threshold of 3x GDP per capita), the total five-dose series must be priced under $105. Furthermore, the "added value" of a vaccine is highest in "pessimistic" scenarios where other prevention methods like ART scale-up are underperforming.

Results and Impact

  • Infections and Mortality: A biennial campaign at 20% coverage could prevent 480,000–650,000 infections (a 13.8–15.3% reduction) and avoid over 44,000 AIDS-related deaths over 10 years.
  • Economic Value: In the main scenario, the ICER was $13,746 per QALY. This is considered cost-effective by international standards (falling below the $16,767 threshold of 3x GDP per capita), though it exceeds more conservative 1x GDP thresholds.

Limitations and Future Directions

The model's primary limitations include a lack of granularity regarding age, gender, and specific high-risk groups (e.g., female sex workers), which might underestimate the potential impact of highly targeted programs. Additionally, the interaction between vaccines and PrEP rollout was not explicitly modeled. Future research should include budget impact analyses to determine the feasibility of the high upfront costs associated with mass campaigns for the South African government.

Conclusion

A partially effective HIV vaccine could have a substantial impact on the South African epidemic. If priced appropriately, biennial vaccination campaigns offer a more effective and cost-efficient path forward than continuous delivery models, providing a clear strategy for deploying next-generation vaccine candidates.

Summary updated

Abstract

Promising multi-dose HIV vaccine regimens are being tested in trials in South Africa. We estimated the potential epidemiological and economic impact of HIV vaccine campaigns compared to continuous vaccination, assuming that vaccine efficacy is transient and dependent on immune response. We used a dynamic economic mathematical model of HIV transmission calibrated to 2012 epidemiological data to simulate vaccination with anticipated antiretroviral treatment scale-up in South Africa. We estimate that biennial vaccination with a 70% efficacious vaccine reaching 20% of the sexually active population could prevent 480,000-650,000 HIV infections (13.8-15.3% of all infections) over 10 years. Assuming a launch price of $15 per dose, vaccination was found to be cost-effective, with an incremental cost-effectiveness ratio of $13,746 per quality-adjusted life-year as compared to no vaccination. Increasing vaccination coverage to 50% will prevent more infections but is less likely to achieve cost-effectiveness. Campaign vaccination is consistently more effective and costs less than continuous vaccination across scenarios. Results suggest that a partially effective HIV vaccine will have substantial impact on the HIV epidemic in South Africa and offer good value if priced less than $105 for a five-dose series. Vaccination campaigns every two years may offer greater value for money than continuous vaccination reaching the same coverage level.
BibTeX
@inproceedings{montigny2018projected,
  author = {Simon de Montigny and Blythe Adamson and Benoı̂t Mâsse and Louis P. Garrison and James G. Kublin and Peter B. Gilbert and Dobromir Dimitrov},
  title = {{Projected effectiveness and added value of HIV vaccination campaigns in South Africa: A modeling study}},
  booktitle = {Scientific},
  year = {2018},
  doi = {10.1038/s41598-018-24268-4},
}
Figure